All-cause mortality rate in patients with idiopathic pulmonary fibrosis: Implications for the design and execution of clinical trials

American Journal of Respiratory and Critical Care Medicine

Volumn 189, Issue 7, 2014, Pages 825-831

  King Jr , Talmadge E ^a   Albera, Carlo ^b   Bradford, Williamson Z ^c   Costabel, Ulrich ^d   Du Bois, Roland M ^e   Leff, Jonathan A ^c   Nathan, Steven D ^f   Sahn, Steven A ^g   Valeyre, Dominique ^h   Noble, Paul W ⁱ  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TURIN   (Italy)

^c InterMune Inc   (United States)

^d RUHRLANDKLINIK   (Germany)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f INOVA FAIRFAX HOSPITAL   (United States)

^g MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^h AVICENNE HOSPITAL   (France)

ⁱ CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Clinical trial; Endpoints; Hospitalization; Idiopathic pulmonary fibrosis; Mortality

Indexed keywords

GAMMA1B INTERFERON; PIRFENIDONE;

ARTICLE; CAUSE OF DEATH; DISEASE COURSE; FIBROSING ALVEOLITIS; FOLLOW UP; FORCED VITAL CAPACITY; HOSPITALIZATION; HUMAN; LUNG FUNCTION; META ANALYSIS; MORTALITY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STUDY DESIGN; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CAUSE OF DEATH; CLINICAL TRIALS, PHASE III AS TOPIC; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INTERFERON-GAMMA; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MODELS, STATISTICAL; PYRIDONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; RESEARCH DESIGN; SAMPLE SIZE; TREATMENT OUTCOME;

EID: 84897459884     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201311-1951OC     Document Type: Article

References (31)

1. American Thoracic Society, European Respiratory Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000; 161:646-664.
2. Safety and efficacy of BIBF 1120 at high dose in idiopathic pulmonary fibrosis patients. ClinicalTrials.gov identifier: NCT01335464 [accessed 2014 Mar 6]. Available from: www.clinicaltrials.gov
3. Safety and efficacy of BIBF 1120 at high dose in idiopathic pulmonary fibrosis patients II. ClinicalTrials.gov identifier: NCT01335477 [accessed 2014 Mar 6]. Available from: www.clinicaltrials.gov
4. Evaluating the effectiveness of prednisone, azathioprine, and N-acetylcysteine in patients with IPF (PANTHER-IPF). ClinicalTrials.gov identifier: NCT00650091 [accessed 2014 Mar 6]. Available from: www.clinicaltrials.gov
5. Efficacy and safety of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF) (ASCEND). ClinicalTrials.gov identifier: NCT01366209 [accessed 2014 Mar 6]. Available from: www.clinicaltrials.gov
6. Raghu G, Collard HR, Anstrom K.J., Flaherty KR, Fleming TR, King TE Jr, Martinez FJ, Brown KK. Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med 2012; 185:1044-1048.
7. King TE Jr., Albera C, Bradford W.Z., Costabel U., du Bois RM, Nathan SD, Sahn SA, Valeyre D, Noble PW All-cause mortality rate in patients with idiopathic pulmonary fibrosis: implications for the design and execution of mortality trials [abstract]. Am J Respir Crit Care Med 2013; 187:A2356.
8. Noble PW, Albera C, Bradford W.Z., Costabel U., Glassberg MK, Kardatzke D, King TE Jr, Lancaster L, Sahn SA, Szwarcberg J, et al.; CAPACITY Study Group. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377:1760-1769.
9. King TE J.r., Albera C, Bradford W.Z., Costabel U., Hormel P, Lancaster L, Noble P.W., Sahn SA, Szwarcberg J, Thomeer M, et al.; INSPIRE Study Group. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 2009; 374:222-228.
10. du Bois R.M., Weycker D, Albera C., Bradford WZ, Costabel U, Kartashov A, King TE Jr, Lancaster L, Noble PW, Sahn SA, et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med 2011; 184:1382-1389.
11. Latsi PI, du Bois RM, Nicholson AG, Colby TV, Bisirtzoglou D, Nikolakopoulou A., Veeraraghavan S, Hansell DM, Wells AU. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003; 168: 531-537.
12. du Bois R.M., Weycker D, Albera C., Bradford WZ, Costabel U, Kartashov A, Lancaster L., Noble PW, Raghu G, Sahn SA, et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 184:459-466.
13. Bradford WZ, Cohen AH, Leff JA Selection of clinically meaningful primary endpoints in phase 3 clinical trials in idiopathic pulmonary fibrosis [letter]. Am J Respir Crit Care Med 2013; 187:1269-1270.
14. Wells AU, Behr J, Costabel U., Cottin V, Poletti V, Richeldi L; European IPF Consensus Group. Hot of the breath: mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good. Thorax 2012; 67:938-940.
15. Mills EJ, Wu P, Chong G., Ghement I, Singh S, Akl E.A., Eyawo O., Guyatt G, Berwanger O, Briel M. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. QJM 2011; 104:109-124.
16. Cheung BM, Lauder IJ, Lau C.P., Kumana CR Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. Br J Clin Pharmacol 2004; 57:640-651.
17. Wilt TJ, Bloomfield HE, MacDonald R, Nelson D., Rutks I, Ho M, Larsen G., McCall A, Pineros S, Sales A. Effectiveness of statin therapy in adults with coronary heart disease. Arch Intern Med 2004; 164:1427-1436.
18. Mills EJ, Rachlis B, Wu P., Devereaux PJ, Arora P, Perri D. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol 2008; 52:1769-1781.
19. Taylor F, Huffman MD, Macedo A.F., Moore THM, Burke M, Davey Smith G, Ward K, Ebrahim S. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013; 1:CD004816.
20. Hotta K, Suzuki E, Di Maio M, Chiodini P, Fujiwara Y., Takigawa N, Ichihara E, Reck M, Manegold C, Pilz L, et al. Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancer. Lung Cancer 2013; 79:20-26.
21. Collard HR, King TE Jr, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003; 168:538-542.
22. Flaherty KR, Mumford JA, Murray S, Kazerooni E.A., Gross BH, Colby TV, Travis WD, Flint A, Toews G.B., Lynch JP III, et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003; 168:543-548.
23. Jegal Y, Kim DS, Shim T.S., Lim CM, Do Lee S, Koh Y, Kim W.S., Kim WD, Lee JS, Travis WD, et al. Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. Am J Respir Crit Care Med 2005; 171:639-644.
24. Zappala CJ, Latsi PI, Nicholson A.G., Colby TV, Cramer D, Renzoni EA, Hansell D.M., du Bois RM, Wells AU. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35:830-836.
25. du Bois R.M., Albera C, Bradford W.Z., Costabel U., Noble PW, Sahn SA, Valeyre D, Weycker D., King TE Jr. A novel clinical prediction model for near-term mortality in patients with idiopathic pulmonary fibrosis [abstract]. Am J Respir Crit Care Med 2013; 187:A2357.
26. du Bois R.M., Weycker D, Albera C., Bradford WZ, Costabel U, Kartashov A, Lancaster L., Noble PW, Sahn SA, Szwarcberg J, et al. Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med 2011; 183: 1231-1237.
27. Holland AE, Hill CJ, Conron M, Munro P., McDonald CF Small changes in six-minute walk distance are important in diffuse parenchymal lung disease. Respir Med 2009; 103:1430-1435.
28. Swigris JJ, Wamboldt FS, Behr J, du Bois RM, King TE, Raghu G, Brown KK The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference. Thorax 2010; 65:173-177.
29. Nathan SA, Albera C, du Bois RM, Bradford WZ, Costabel U, King TE Jr, Noble PW, Sahn SA, Valeyre D. 6-Minute walk test in patients with idiopathic pulmonary fibrosis: confirmation of the minimal clinically important difference [abstract]. Eur Respir J 2012; 40:665s.
30. Sahn SA, Albera C, du Bois RM, Bradford WZ, Costabel U, King TE Jr, Noble PW, Valeyre D. The effect of treatment with pirfenidone on progression-free survival in patients with idiopathic pulmonary fibrosis: exploratory analysis of outcomes using novel criteria for disease progression [abstract]. Am J Respir Crit Care Med 2011; 183:A3810.
31. Ley B, Ryerson CJ, Vittinghoff E, Ryu J.H., Tomassetti S., Lee JS, Poletti V, Buccioli M, Elicker B.M., Jones KD, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 2012; 156:684-691.